fenofibric acid has been researched along with bezafibrate in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Chapman, JM; Kliewer, SA; Koble, CS; Lehmann, JM; Lewis, MC; Moore, LB; Plunket, KD; Sundseth, SS; Willson, TM; Wilson, JG; Winegar, DA; Wu, Z | 1 |
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Aoki, T; Asaki, T; Hamamoto, T; Kuwabara, K; Murakami, K; Ohmachi, S; Sugiyama, Y; Todo, M | 2 |
| Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
| Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
| Kashihara, M; Mizuguchi, M; Yokoyama, T | 1 |
| Sermukslis, B; Smud, R | 1 |
| Leiss, O; Meyer-Krahmer, K; von Bergmann, K | 1 |
| Acuña, AM; Gladstein, J; Tesone, PA | 1 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Sznajderman, M | 1 |
| Leiss, O; von Bergmann, K | 1 |
| Harvengt, C; Heller, F | 1 |
| Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K | 1 |
| Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
| Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Fukuhara, H; Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
6 trial(s) available for fenofibric acid and bezafibrate
| Article | Year |
|---|---|
Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Propionates; Triglycerides | 1987 |
Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Propionates; Sex Factors; Triglycerides | 1985 |
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
[Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clinical Trials as Topic; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Propionates; Triglycerides | 1984 |
Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
Topics: Bezafibrate; Bile; Cholesterol; Female; Fenofibrate; Gallbladder; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Male; Propionates; Triglycerides | 1984 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates | 1982 |
14 other study(ies) available for fenofibric acid and bezafibrate
| Article | Year |
|---|---|
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
Topics: Animals; Butyrates; DNA-Binding Proteins; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Mice; Nuclear Proteins; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Zinc Fingers | 1999 |
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |
Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Combinatorial Chemistry Techniques; Dioxanes; Humans; Mice; Molecular Structure; Oxazoles; PPAR alpha; Structure-Activity Relationship | 2008 |
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred Strains; Molecular Structure; Oxazoles; PPAR alpha; Structure-Activity Relationship; Triglycerides | 2008 |
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning; Humans; Prealbumin; Thermodynamics; Triclabendazole | 2021 |
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Middle Aged; Phospholipids; Propionates; Triglycerides | 1986 |
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
Topics: Adult; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Humans; Hypolipidemic Agents; Lipase; Lipolysis; Lipoprotein Lipase; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Probucol; Triglycerides | 1983 |
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein | 1994 |
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity | 1996 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography.
Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; PPAR alpha; Rats; Rats, Wistar; Reproducibility of Results; RNA, Messenger | 2014 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |